PeptiDream Inc. (4587.T)
JPY 2603.5
(-0.53%)
JPY 2603.5
(-0.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.77 Billion JPY | -20.1% |
| 2022 | 8.98 Billion JPY | 103.26% |
| 2021 | 4.41 Billion JPY | -36.81% |
| 2020 | 6.99 Billion JPY | 494.02% |
| 2019 | -1.77 Billion JPY | -149.57% |
| 2018 | 3.57 Billion JPY | 22.98% |
| 2017 | 2.91 Billion JPY | 16.89% |
| 2016 | 2.49 Billion JPY | -2.26% |
| 2015 | 2.54 Billion JPY | 83.17% |
| 2014 | 1.39 Billion JPY | 590.86% |
| 2013 | 201.36 Million JPY | 25.22% |
| 2012 | 160.81 Million JPY | 984.93% |
| 2011 | -18.17 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 25.77 Billion JPY | 2457.48% |
| 2024 Q1 | -1.09 Billion JPY | -3338.77% |
| 2023 Q1 | -295.18 Million JPY | -103.14% |
| 2023 Q2 | -719.51 Million JPY | -143.75% |
| 2023 Q3 | 7.73 Billion JPY | 1175.58% |
| 2023 Q4 | 33.76 Million JPY | -99.56% |
| 2023 FY | 7.17 Billion JPY | -20.1% |
| 2022 FY | 8.98 Billion JPY | 103.26% |
| 2022 Q4 | 9.4 Billion JPY | 659.29% |
| 2022 Q2 | 351.85 Million JPY | 130.16% |
| 2022 Q1 | -1.16 Billion JPY | -1314.94% |
| 2022 Q3 | 1.23 Billion JPY | 252.11% |
| 2021 Q4 | -82.45 Million JPY | -102.29% |
| 2021 FY | 4.41 Billion JPY | -36.81% |
| 2021 Q2 | -393.02 Million JPY | -191.3% |
| 2021 Q3 | 3.59 Billion JPY | 1015.44% |
| 2021 Q1 | 430.46 Million JPY | -92.82% |
| 2020 Q1 | -481.27 Million JPY | 0.0% |
| 2020 FY | 6.99 Billion JPY | 494.02% |
| 2020 Q4 | 5.99 Billion JPY | 3466.14% |
| 2020 Q3 | -178.03 Million JPY | -110.74% |
| 2020 Q2 | 1.65 Billion JPY | 444.44% |
| 2019 Q1 | 120.47 Million JPY | -82.38% |
| 2019 Q2 | 2.9 Billion JPY | 2310.37% |
| 2019 FY | -1.77 Billion JPY | -149.57% |
| 2019 Q3 | -412.83 Million JPY | -114.22% |
| 2018 Q2 | 4.23 Billion JPY | 1079.53% |
| 2018 Q3 | -128.14 Million JPY | -103.02% |
| 2018 Q1 | -432.82 Million JPY | -420.83% |
| 2018 Q4 | 683.65 Million JPY | 633.51% |
| 2018 FY | 3.57 Billion JPY | 22.98% |
| 2017 FY | 2.91 Billion JPY | 16.89% |
| 2017 Q4 | 134.9 Million JPY | 113.09% |
| 2017 Q3 | -1.03 Billion JPY | -143.26% |
| 2017 Q2 | 2.38 Billion JPY | 1101.74% |
| 2017 Q1 | -237.83 Million JPY | -583.23% |
| 2016 FY | 2.49 Billion JPY | -2.26% |
| 2016 Q3 | 380.54 Million JPY | -62.2% |
| 2016 Q4 | -34.81 Million JPY | -109.15% |
| 2016 Q2 | 1 Billion JPY | -14.22% |
| 2016 Q1 | 1.17 Billion JPY | 301.87% |
| 2015 Q3 | 75.51 Million JPY | -94.84% |
| 2015 FY | 2.54 Billion JPY | 83.17% |
| 2015 Q2 | 1.46 Billion JPY | 2612.74% |
| 2015 Q1 | -58.26 Million JPY | -210.07% |
| 2015 Q4 | 292.06 Million JPY | 286.76% |
| 2014 Q1 | -32.54 Million JPY | -121.74% |
| 2014 Q4 | 52.92 Million JPY | 178.45% |
| 2014 Q3 | -67.46 Million JPY | -198.39% |
| 2014 Q2 | 68.57 Million JPY | 310.67% |
| 2014 FY | 1.39 Billion JPY | 590.86% |
| 2013 FY | 201.36 Million JPY | 25.22% |
| 2013 Q2 | 19.43 Million JPY | 0.0% |
| 2013 Q3 | 15.63 Million JPY | -19.52% |
| 2013 Q4 | 149.7 Million JPY | 857.3% |
| 2012 FY | 160.81 Million JPY | 984.93% |
| 2011 FY | -18.17 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | -1034.852% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 1463.148% |
| GNI Group Ltd. | 13.1 Billion JPY | 48.332% |
| Linical Co., Ltd. | 725.72 Million JPY | -833.281% |
| Trans Genic Inc. | 89.43 Million JPY | -7473.066% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 574.984% |
| Soiken Holdings Inc. | -610 Million JPY | 1210.323% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 976.495% |
| AnGes, Inc. | -11.96 Billion JPY | 156.595% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 704.305% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 171.101% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -6393.875% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 883.541% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 706.372% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 636.692% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 948.16% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 2107.632% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 662.0% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 607.118% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 450.938% |
| Ribomic Inc. | -1.11 Billion JPY | 706.799% |
| SanBio Company Limited | -4.53 Billion JPY | 249.219% |
| Healios K.K. | -3.37 Billion JPY | 300.445% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 686.371% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 586.042% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 582.755% |
| StemRIM | -2.07 Billion JPY | 426.255% |
| CellSource Co., Ltd. | 1.22 Billion JPY | -454.486% |
| FunPep Company Limited | -994 Million JPY | 781.393% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 862.077% |
| Stella Pharma Corporation | -760.3 Million JPY | 990.839% |
| TMS Co., Ltd. | -943.25 Million JPY | 818.052% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 973.501% |
| Cuorips Inc. | -588.48 Million JPY | 1250.926% |
| K Pharma,Inc. | 366.05 Million JPY | -1750.271% |
| Takara Bio Inc. | 3 Billion JPY | -125.543% |
| ReproCELL Incorporated | -409.29 Million JPY | 1754.816% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -61122.516% |
| StemCell Institute Inc. | 413.75 Million JPY | -1536.955% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | -4587.003% |
| CellSeed Inc. | -697.77 Million JPY | 1070.662% |